News | April 12, 2024
Generics gain ground, yet HCPs still favor branded drugs, finds GlobalData
A significant proportion of healthcare professionals still tend to favor branded drugs
A significant proportion of healthcare professionals still tend to favor branded drugs
The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year
A new GSK survey shows a large number of adults do not understand how shingles may be triggered
SVB Financial Group and its subsidiaries were involved in over $1.4 billion in total venture financing raised from 2010 to 2022 for drug development
Analysis of Post-Marketing Safety Data Shows Consistent Findings with Safety Profile Reported in Clinical Trials of Edaravone
The Innovation Explorer database of GlobalData’s Disruptor Intelligence Center highlights how blockchain ensures the authenticity of products thereby, improves trust, traceability, and transparency across key sectors
Acute asthma attack is a common cause of admission to emergency departments (EDs) among children, and triage by severity is important for determining appropriate clinical treatment
The Mechanisms of Inherited Kidney Disorders (MIKADO) group at the University of Zurich (UZH) and Insilico Medicine will be working together to identify, rank, and annotate novel drug targets to identify potential therapeutics for cystinosis
The group, known as the HIV Obstruction by Programmed Epigenetics (HOPE) Collaboratory, will be led by researchers at Gladstone Institutes, Scripps Research Florida, and Weill Cornell Medicine. Their approach, which aims to both silence and permanently remove HIV from the body, takes advantage of knowledge about how other viruses have become naturally inactivated over time.
Additional data from APPRAISE ATP trial reinforce modular therapy approach
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)